The Association of CCND1 Overexpression and Cisplatin Resistance in Testicular Germ Cell Tumors and Other Cancers
Elodie Noël(Queen Mary University of London), Yong‐Jie Lu(Queen Mary University of London), Jackie Perry(Tumour Institute of Tuscany), Ling Shan(Royal Netherlands Academy of Arts and Sciences), Ningfeng Fiona Li(Queen Mary University of London), Marc Yeste‐Velasco(Queen Mary University of London), Alan McIntyre(University of Nottingham), Xueying Mao(Ministry of Education), Bryan D. Young(The University of Texas Southwestern Medical Center), Daniel M. Berney(Queen Mary University of London), R.T.D. Oliver(University of Cambridge), Thomas Powles(Queen Mary University of London), Liyan Xue(Queen Mary University of London), Simon P. Joel(Brain Tumour Research), Sakunthala C. Kudahetti(Queen Mary University of London), Janet Shipley(Institute of Cancer Research), Swee Y. Sharp(Institute of Cancer Research), Tracy Chaplin(Queen Mary University of London)
Cited by 103
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k